Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Homologous Recombination Deficiency (HRD) Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAD51 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAD51 Recombinant Protein (Full-Length / Key Domains) High purity (>95%), Endotoxin Controlled, Sequence Verified. Optimized for biochemical assays. |
View RAD51 Products |
| Gene Delivery | RAD51 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and homologous recombination assays. |
View RAD51 Products |
| Benchmark Ab | Anti-RAD51 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and immunofluorescence (foci formation). |
View RAD51 Products |
| Validator | RAD51 siRNA Set For target knockdown verification and specificity profiling. |
View RAD51 Products |
| Related Target A | BRCA2 Essential mediator of RAD51 filament assembly; primary partner for protein-protein interaction (PPI) inhibitors. |
View BRCA2 Products |
| Related Target B | PARP1 Synergistic target in homologous recombination deficient (HRD) tumors; key for combination therapy screening. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Oligomerization & Aggregation Control | Recombinant RAD51 proteins characterized by SEC-MALS to ensure defined, monodisperse oligomeric state. |
| PPI Disruption Screening (RAD51-BRCA2) | Sequence-verified RAD51 and BRCA2 BRC repeat peptide panels optimized for TR-FRET and FP assays. |
| Lack of Controls | High-affinity clinical benchmark recombinant antibodies included. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for orthogonal genetic knockdown verification in cellular assays. |
Live RAD51 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RAD51 is gaining significant momentum as a powerful strategy to overcome resistance to PARP inhibitors and traditional DNA-damaging chemotherapies. As a key recombinase in the homologous recombination repair (HRR) pathway, RAD51 enables cancer cells to survive double-strand breaks. The race for RAD51 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic combinations to highly targeted small molecule inhibitors that disrupt the RAD51-BRCA2 interface or inhibit RAD51 multimerization. As first-generation therapies reach clinical evaluation, the next wave of R&D is targeting synthetic lethal interactions in BRCA-proficient and HR-competent tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Ideaya Biosciences, Artios Pharma | Breast, Ovarian, Prostate Cancer (PARP-resistant) | Homogeneous assay reagents (SEC-verified RAD51 and BRCA2 peptide controls) |
| Small Molecule (ATPase Inhibitors) | Schrodinger, Inc. | Solid Tumors, Hematological Malignancies | High-purity active enzyme for enzymatic screening (Endotoxin <1EU/ug) |
| Combination Biologics | Academic Institutions, Biotech Consortia | HRD-positive refractory cancers | Lentivirus-mediated RAD51 overexpression for functional rescue assays |